Dozens report side effects in first month of Mounjaro’s rollout in Korea
At least 35 cases of side effects, including two serious ones, were reported within a month of weight loss drug Mounjaro’s release in Korea, raising safety concerns amid surging demand. According to data obtained by Rep. Seo Mi-hwa of the ruling Democratic Party of Korea from the Korea Institute of Drug Safety and Risk Management, the cases were reported between August and September, following the local rollout of Mounjaro, whose active ingredient is tirzepatide. Health officials said two of the 35 reported cases met the threshold for a serious reaction, with symptoms such as diarrhea and hypoglycemic shock. Under Korean drug safety regulations, serious adverse events are defined as those that lead to death, are life-threatening, require hospitalization or produce permanent impairment. Fifteen cases involved women and four involved men, while the gender of the remaining 16 patients was not reported. Seven cases were reported among people between the ages of 19 and 65, with no age data given for the others. Common side effects linked to tirzepatide include gastrointestinal distress, ab
Dec 10, 2025By Lee Hae-rin